Leading Single-Cell Genomics Market Companies: A Detailed Profile

By /

Single-Cell Genomics Market Companies

Single-Cell Genomics Market Companies
  • 10x Genomics
  • Illumina, Inc.
  • Fluidigm Corporation (Standard BioTools)
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • BGI Genomics Co., Ltd.
  • Takara Bio, Inc.
  • Mission Bio, Inc.
  • NanoString Technologies, Inc.
  • QIAGEN N.V.
  • Oxford Nanopore Technologies
  • PerkinElmer, Inc.
  • Roche Sequencing Solutions
  • Agilent Technologies, Inc.
  • Dolomite Bio (Blacktrace Holdings)
  • Zymo Research Corporation
  • SeqWell, Inc.
  • Parse Biosciences
  • Novogene Corporation
  • Singleron Biotechnologies

Get Sample Report

1. 10x Genomics

  • Company Name and Headquarters: 10x Genomics, Inc., Pleasanton, California, USA

  • Product Offerings: 10x Genomics is a leader in single-cell and spatial genomics. Their flagship Chromium System enables high-throughput single-cell gene expression, immune profiling, ATAC (Assay for Transposase-Accessible Chromatin using sequencing), and multiome (joint profiling of gene expression and chromatin accessibility). They also offer the Visium Spatial Gene Expression solution for spatially resolved transcriptomics. Their product portfolio includes instruments, reagents, and software (Cell Ranger, Loupe Browser).

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): 10x Genomics holds a dominant position in the single-cell genomics market, particularly for single-cell gene expression. While specific revenue breakdown for “single-cell genomics” isn’t always reported separately, their overall revenue in 2023 was approximately $614 million, with a significant portion derived from their single-cell and spatial solutions. They are often cited as having the largest market share in the core single-cell sequencing workflow.

  • Recent Developments, Partnerships, or Innovations:

    • Xenium In Situ platform: A major recent innovation for high-resolution in situ analysis of RNA, competing with other spatial platforms.

    • Chromium iX: Next-generation instrument for single-cell analysis, offering increased throughput and automation.

    • Continuous expansion of assay chemistries and software improvements.

    • Partnerships with academic institutions and pharmaceutical companies to drive adoption and applications.

  • Competitive Positioning and Strategic Focus: 10x Genomics is positioned as a premium provider with innovative, high-performance, and user-friendly solutions. Their strategic focus is on expanding the applications of single-cell and spatial genomics across various research areas (oncology, neuroscience, immunology, developmental biology) and translating these technologies into clinical research. They invest heavily in R&D to maintain their technological leadership.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, contract research organizations (CROs), government research labs.

2. Illumina, Inc.

  • Company Name and Headquarters: Illumina, Inc., San Diego, California, USA

  • Product Offerings: While not primarily a single-cell workflow company, Illumina is the dominant provider of next-generation sequencing (NGS) instruments, reagents, and software globally. Their sequencers (e.g., NovaSeq, NextSeq, MiSeq) are essential for sequencing libraries prepared by single-cell genomics platforms from other vendors (like 10x Genomics, Parse Biosciences, etc.). They also offer some targeted single-cell solutions through partnerships or acquisitions (e.g., related to their Bio-Rad partnership for ddPCR).

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Illumina’s revenue is primarily from NGS. While they don’t have a direct single-cell “segment” revenue, a substantial portion of their sequencer and reagent sales are driven by single-cell genomics research. Their overall revenue in 2023 was approximately $4.5 billion. Their market share in NGS is over 70-80%.

  • Recent Developments, Partnerships, or Innovations:

    • NovaSeq X Series: Their latest high-throughput sequencers, crucial for large-scale single-cell and spatial genomics projects.

    • Partnerships with single-cell solution providers to ensure compatibility and optimize workflows.

    • Ongoing development of sequencing chemistries to improve data quality and throughput.

  • Competitive Positioning and Strategic Focus: Illumina’s strategic focus is on maintaining its leadership in NGS technology, expanding into clinical applications, and enabling a vast ecosystem of genomics research, including single-cell. They aim to make sequencing more accessible and cost-effective.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, clinical diagnostic labs, government labs, agriculture, forensics.

3. Fluidigm Corporation (Standard BioTools)

  • Company Name and Headquarters: Standard BioTools (formerly Fluidigm Corporation), South San Francisco, California, USA

  • Product Offerings: Fluidigm was a pioneer in microfluidics for single-cell analysis. Their flagship products included the C1 Single-Cell Auto Prep System for isolating, reverse transcribing, and amplifying individual cells, and the Biomark HD system for high-throughput gene expression and genotyping. With the rebranding to Standard BioTools, they continue to focus on tools for high-parameter biology, including their CyTOF (Cytometry by Time-Of-Flight) mass cytometry platforms for high-dimensional protein analysis at single-cell resolution (Helios, Hyperion Imaging System).

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Standard BioTools’ single-cell genomics market share (specifically for RNA-seq) has decreased with the rise of droplet-based methods. Their primary single-cell focus has shifted more towards mass cytometry for proteomics. Their total revenue in 2023 was approximately $107 million.

  • Recent Developments, Partnerships, or Innovations:

    • Focus on the CyTOF platform and its applications in immunology and oncology.

    • Acquisition of SomaLogic to create a proteomics-focused entity, further emphasizing their shift away from pure single-cell genomics.

  • Competitive Positioning and Strategic Focus: Standard BioTools is positioned as a provider of high-parameter single-cell analysis tools, particularly in proteomics. Their strategic focus is on leveraging mass cytometry and expanding into clinical and translational research, especially for biomarker discovery and drug development.

  • Key Customers or Industries Served: Academic research institutions, immunology and oncology researchers, pharmaceutical and biotechnology companies.

4. Bio-Rad Laboratories, Inc.

  • Company Name and Headquarters: Bio-Rad Laboratories, Inc., Hercules, California, USA

  • Product Offerings: Bio-Rad offers a range of tools relevant to single-cell genomics, most notably their ddSEQ Single-Cell Isolator System, which utilizes droplet digital PCR (ddPCR) technology for high-throughput single-cell gene expression analysis. They also provide instruments and reagents for PCR, qPCR, protein analysis, and cell biology, which can complement single-cell workflows.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Bio-Rad has a niche but significant presence in single-cell genomics, particularly for targeted gene expression and variant detection using ddPCR. Their overall revenue in 2023 was approximately $2.7 billion. Revenue specifically from single-cell genomics is not separately reported but contributes to their Life Science segment.

  • Recent Developments, Partnerships, or Innovations:

    • Ongoing development of ddPCR applications for sensitive detection of rare cells and variants.

    • Partnership with Illumina to develop a single-cell sequencing solution (although this has seen limited market penetration compared to other players).

  • Competitive Positioning and Strategic Focus: Bio-Rad focuses on providing robust and sensitive tools for molecular detection. Their single-cell genomics strategy leverages their expertise in microfluidics and PCR, offering solutions for specific applications like rare cell analysis and biomarker validation.

  • Key Customers or Industries Served: Academic research institutions, clinical diagnostic labs, pharmaceutical and biotechnology companies.

5. Thermo Fisher Scientific Inc.

  • Company Name and Headquarters: Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA

  • Product Offerings: As a global scientific instrumentation giant, Thermo Fisher offers a vast array of products that touch single-cell genomics at various stages. This includes instruments for cell isolation (e.g., flow cytometers like the Attune NxT Acoustic Focusing Cytometer), RNA and DNA extraction kits, PCR and qPCR systems, and sequencing platforms (Ion Torrent Genexus System for targeted sequencing, although less dominant than Illumina for whole-transcriptome single-cell sequencing). They also provide a broad range of reagents, consumables, and bioinformatics tools.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Thermo Fisher’s presence in single-cell genomics is broad but fragmented across its product lines. They are not a primary single-cell workflow provider in the same way as 10x Genomics. Their overall revenue in 2023 was approximately $42.8 billion.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous development of their flow cytometry portfolio for high-throughput cell sorting and analysis.

    • Expansion of their molecular biology reagents and consumables.

    • Strategic acquisitions to fill gaps in their portfolio (e.g., potentially looking at spatial biology companies).

  • Competitive Positioning and Strategic Focus: Thermo Fisher offers an extensive ecosystem of tools and reagents that support single-cell genomics research. Their strategic focus is on being a comprehensive solutions provider, offering flexibility and choice across different stages of the research workflow.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, clinical diagnostic labs, industrial labs, government labs.

6. BGI Genomics Co., Ltd.

  • Company Name and Headquarters: BGI Genomics Co., Ltd., Shenzhen, China

  • Product Offerings: BGI is a leading global genomics organization. In single-cell genomics, they offer complete solutions, including their DNBSEQ sequencing platforms (e.g., DNBSEQ-T7, MGISEQ-2000), which compete with Illumina. They also have proprietary single-cell analysis platforms, such as the Stereo-seq (Spatially Resolved Transcriptomics) technology for spatial gene expression and single-cell sequencing services. They provide instruments, reagents, and comprehensive sequencing services.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): BGI is a significant player globally, particularly in Asia. Their sequencing platforms are gaining traction. While specific single-cell revenue is not disclosed, their overall revenue in 2023 was approximately $510 million USD.

  • Recent Developments, Partnerships, or Innovations:

    • Stereo-seq: A high-resolution spatial transcriptomics technology that offers high throughput and resolution.

    • Development of new sequencing platforms and chemistries.

    • Expansion of their global sequencing service offerings.

  • Competitive Positioning and Strategic Focus: BGI positions itself as a cost-effective and high-throughput sequencing provider, challenging Illumina’s dominance. Their strategic focus is on expanding their global footprint, particularly with their proprietary sequencing technology and advancing spatial genomics with Stereo-seq.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, clinical diagnostic labs, agricultural genomics.

7. Takara Bio, Inc.

  • Company Name and Headquarters: Takara Bio, Inc., Shiga, Japan

  • Product Offerings: Takara Bio offers a range of tools for single-cell analysis, primarily focusing on sample preparation and library construction. Their key products include the Smart-seq (Switching Mechanism at 5′ End of RNA Template) kits for full-length single-cell RNA-seq, which are well-regarded for their sensitivity and ability to capture splice variants. They also provide single-cell DNA amplification kits and instruments for cell manipulation.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Takara Bio has a strong presence in the manual and low-to-medium throughput single-cell RNA-seq market with their Smart-seq kits. Their overall revenue in 2023 was approximately $780 million USD.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous improvement of their Smart-seq kits for various applications.

    • Development of new reagents for single-cell multiomics.

    • Focus on providing comprehensive solutions for advanced molecular biology research.

  • Competitive Positioning and Strategic Focus: Takara Bio is positioned as a provider of high-quality, sensitive reagents for single-cell library preparation, particularly for researchers needing full-length transcript information or working with small numbers of cells. Their strategic focus is on enabling deeper biological insights through advanced molecular tools.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, core genomics labs.

8. Mission Bio, Inc.

  • Company Name and Headquarters: Mission Bio, Inc., South San Francisco, California, USA

  • Product Offerings: Mission Bio is a specialized single-cell genomics company focused on targeted multi-omics, specifically for DNA and protein analysis. Their Tapestri Platform uses droplet microfluidics to analyze DNA mutations and protein expression at single-cell resolution. It’s particularly strong for detecting rare clones, tracking disease progression, and understanding resistance mechanisms in cancer and other diseases.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Mission Bio has a strong niche in targeted single-cell DNA and multi-omics. While precise revenue figures for their single-cell segment aren’t public, they are a significant player in their specific niche.

  • Recent Developments, Partnerships, or Innovations:

    • Expansion of their Tapestri panel offerings to cover a wider range of cancer types and research applications.

    • Introduction of protein analysis capabilities on the Tapestri platform, enabling simultaneous DNA and protein detection.

    • Partnerships with pharmaceutical companies for companion diagnostics and drug development.

  • Competitive Positioning and Strategic Focus: Mission Bio is uniquely positioned for highly sensitive, targeted single-cell DNA and multi-omics analysis, particularly in oncology and inherited diseases. Their strategic focus is on enabling clinical and translational research, from biomarker discovery to monitoring minimal residual disease.

  • Key Customers or Industries Served: Oncology researchers, hematologists, pharmaceutical and biotechnology companies, clinical research labs.

9. NanoString Technologies, Inc.

  • Company Name and Headquarters: NanoString Technologies, Inc., Seattle, Washington, USA

  • Product Offerings: NanoString is a key player in spatial biology and single-cell analysis. Their CosMx Spatial Molecular Imager (SMI) offers high-resolution in situ analysis of RNA and protein, enabling single-cell and subcellular spatial profiling. They also have the GeoMx Digital Spatial Profiler (DSP) for larger-scale spatial analysis. Their nCounter platform also allows for highly multiplexed gene expression analysis without amplification, which can be applied to bulk and sometimes limited single-cell samples.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): NanoString has a significant and growing presence in the spatial biology market, which increasingly converges with single-cell analysis. Their overall revenue in 2023 was approximately $160 million.

  • Recent Developments, Partnerships, or Innovations:

    • CosMx SMI: Major launch providing single-cell and subcellular resolution spatial analysis.

    • Continuous expansion of their probe sets and applications for both CosMx and GeoMx.

    • Focus on clinical applications of spatial biology, particularly in oncology.

  • Competitive Positioning and Strategic Focus: NanoString is a leader in spatial biology, offering both high-resolution (CosMx) and high-plex (GeoMx) solutions. Their strategic focus is on enabling a deeper understanding of tissue architecture and cellular interactions in disease, with a strong push into translational and clinical research.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, oncology researchers, immunology researchers.

10. QIAGEN N.V.

  • Company Name and Headquarters: QIAGEN N.V., Venlo, Netherlands

  • Product Offerings: QIAGEN is a global provider of sample and assay technologies. While not a primary single-cell workflow vendor, they offer critical components used in single-cell genomics, including kits for nucleic acid extraction (DNA and RNA from minute samples), cDNA synthesis, PCR, and NGS library preparation. Their QIAseq single-cell RNA-seq kits offer a solution for low-input single-cell RNA sequencing. They also provide bioinformatics software.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): QIAGEN’s presence in single-cell genomics is mainly through its reagents and consumables that integrate into various workflows. Their overall revenue in 2023 was approximately $2.0 billion.

  • Recent Developments, Partnerships, or Innovations:

    • Development of new and improved sample preparation kits for low-input and single-cell applications.

    • Expansion of their bioinformatics tools for analyzing single-cell data.

    • Focus on integrated workflows for molecular diagnostics.

  • Competitive Positioning and Strategic Focus: QIAGEN’s strategy is to provide essential tools and solutions across the molecular biology workflow, supporting single-cell research indirectly through high-quality sample preparation and analysis reagents. They aim to simplify and standardize complex molecular workflows.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, clinical diagnostic labs, applied testing labs.

11. Oxford Nanopore Technologies

  • Company Name and Headquarters: Oxford Nanopore Technologies plc, Oxford, UK

  • Product Offerings: Oxford Nanopore Technologies (ONT) offers a revolutionary real-time, long-read sequencing technology based on nanopores. Their sequencers (e.g., MinION, GridION, PromethION) can be used for single-cell applications, particularly for full-length transcript sequencing, splice variant detection, and methylation profiling, providing unique advantages over short-read technologies. While not offering a dedicated single-cell isolation platform, their sequencing technology is highly compatible with various single-cell library preparation methods.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): ONT is a rapidly growing player in the sequencing market, challenging Illumina’s short-read dominance. Their single-cell market share is growing, particularly in niche applications benefiting from long reads. Their overall revenue in 2023 was approximately $208 million USD.

  • Recent Developments, Partnerships, or Innovations:

    • Improvements in sequencing accuracy, throughput, and chemistry (e.g., Q20+ chemistry).

    • Development of new flow cells and devices, making sequencing more accessible.

    • Active community development of single-cell RNA-seq and multiomics workflows utilizing nanopore sequencing.

  • Competitive Positioning and Strategic Focus: ONT is positioned as a disruptive innovator offering portable, real-time, and long-read sequencing. Their strategic focus is on expanding the applications of nanopore sequencing, including in single-cell and spatial biology, by providing unique insights not possible with short-read platforms.

  • Key Customers or Industries Served: Academic research institutions, infectious disease surveillance, environmental genomics, agricultural genomics, some clinical research.

12. PerkinElmer, Inc.

  • Company Name and Headquarters: PerkinElmer, Inc., Waltham, Massachusetts, USA

  • Product Offerings: PerkinElmer provides a broad portfolio of instruments, reagents, and services for various life science applications. In single-cell genomics, their offerings include cell imaging systems (e.g., Opera Phenix, Operetta CLS) for high-content analysis of single cells, automated liquid handling systems, and reagents for cell proliferation and viability assays. While they don’t have a dedicated single-cell sequencing platform, their tools are used upstream for cell isolation, quality control, and functional analysis of single cells.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): PerkinElmer’s single-cell genomics presence is indirect, supporting various stages of single-cell workflows through their broader life science tools. Their overall revenue in 2023 was approximately $2.7 billion.

  • Recent Developments, Partnerships, or Innovations:

    • Focus on enhancing high-content imaging and analysis capabilities for cellular phenotyping.

    • Development of automation solutions to streamline laboratory workflows.

  • Competitive Positioning and Strategic Focus: PerkinElmer aims to be a comprehensive provider of solutions for cellular analysis and drug discovery. Their strategic focus is on integrating their diverse product lines to offer complete workflows for life science research, including aspects of single-cell biology.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies, academic research institutions, clinical diagnostic labs.

13. Roche Sequencing Solutions (part of F. Hoffmann-La Roche Ltd)

  • Company Name and Headquarters: Roche Sequencing Solutions (Roche Diagnostics), Basel, Switzerland

  • Product Offerings: Roche is a global healthcare company with a significant diagnostics division. While they do not have a dominant single-cell sequencing platform, they offer solutions relevant to single-cell genomics through their broader portfolio. This includes target enrichment panels (e.g., KAPA HyperCap, NimbleGen) that can be used for targeted sequencing of single-cell libraries, as well as reagents and instruments for PCR and other molecular diagnostics. Their acquisition of Flatiron Health and Foundation Medicine points to a focus on clinical genomics, including aspects of single-cell analysis in oncology.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Roche’s primary focus is on clinical diagnostics and therapeutics. Their contribution to single-cell genomics is mostly through targeted sequencing components and potential future clinical applications. Roche Diagnostics overall revenue in 2023 was approximately $15.5 billion USD.

  • Recent Developments, Partnerships, or Innovations:

    • Development of advanced diagnostic tests leveraging genomic information, potentially including single-cell insights.

    • Integration of genomic data into clinical decision-making.

  • Competitive Positioning and Strategic Focus: Roche’s strategic focus is on advancing personalized healthcare through innovative diagnostics and therapeutics. Their approach to single-cell genomics is likely to be driven by its utility in clinical applications, particularly in oncology for understanding tumor heterogeneity and treatment response.

  • Key Customers or Industries Served: Clinical diagnostic labs, hospitals, pharmaceutical companies, academic medical centers.

14. Agilent Technologies, Inc.

  • Company Name and Headquarters: Agilent Technologies, Inc., Santa Clara, California, USA

  • Product Offerings: Agilent provides a wide range of analytical instruments and consumables for the life sciences. In single-cell genomics, their key contributions include instruments for nucleic acid quality control (e.g., Bioanalyzer, Tapestation, Fragment Analyzer) which are essential for assessing single-cell libraries. They also offer SureSelect target enrichment panels, microarrays, and automated liquid handling systems.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Agilent’s role in single-cell genomics is primarily as a provider of essential QC tools and upstream/downstream technologies. Their overall revenue in 2023 was approximately $6.8 billion.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous improvement of their analytical tools for high-sensitivity nucleic acid analysis.

    • Development of automation solutions for genomics workflows.

  • Competitive Positioning and Strategic Focus: Agilent positions itself as a provider of reliable and high-performance analytical tools crucial for ensuring the quality and integrity of genomic experiments. Their strategic focus is on supporting robust and reproducible research workflows, including those in single-cell genomics.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, analytical testing labs, clinical research labs.

15. Dolomite Bio (Blacktrace Holdings)

  • Company Name and Headquarters: Dolomite Bio (part of Blacktrace Holdings), Royston, UK

  • Product Offerings: Dolomite Bio specializes in microfluidics systems for single-cell research. Their key products include the Nadia Instrument for high-throughput single-cell encapsulation and library preparation (e.g., Nadia Innovate for R&D, Nadia Go for routine use). They also offer microfluidic chips, reagents, and associated software, focusing on droplet-based single-cell RNA-seq and other multi-omics applications.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Dolomite Bio has a smaller but growing market share, particularly for researchers who prefer open, flexible microfluidic platforms or those with specific custom requirements. Revenue is not publicly disclosed for the single-cell segment, but they are recognized as a focused player.

  • Recent Developments, Partnerships, or Innovations:

    • Introduction of the Nadia Go for simplified and more accessible single-cell RNA-seq.

    • Development of new applications for their microfluidic platforms, including single-cell multi-omics.

    • Focus on user-friendliness and flexibility for research applications.

  • Competitive Positioning and Strategic Focus: Dolomite Bio positions itself as an accessible and flexible microfluidics platform for single-cell research, offering a balance between throughput and customization. Their strategic focus is on making single-cell experimentation easier and more versatile for a wider range of researchers.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, core genomics facilities.

16. Zymo Research Corporation

  • Company Name and Headquarters: Zymo Research Corporation, Irvine, California, USA

  • Product Offerings: Zymo Research is known for its expertise in nucleic acid purification and epigenetics. While not a single-cell workflow provider, they offer essential kits and reagents for low-input DNA/RNA extraction, quality control, and particularly for epigenomic analysis (e.g., single-cell bisulfite sequencing kits for methylation analysis). Their products are often used upstream in single-cell workflows, especially when working with challenging samples or needing high-quality nucleic acids from limited input.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Zymo Research’s presence in single-cell genomics is through its specialized reagents. Their overall revenue is not publicly disclosed, but they are a well-regarded supplier in the molecular biology space.

  • Recent Developments, Partnerships, or Innovations:

    • Development of improved kits for ultra-low input nucleic acid extraction and purification.

    • Focus on robust and reliable epigenetics tools.

  • Competitive Positioning and Strategic Focus: Zymo Research focuses on providing high-performance, easy-to-use solutions for nucleic acid purification and epigenetics. Their strategic focus is on supporting cutting-edge molecular research by ensuring the quality and integrity of samples.

  • Key Customers or Industries Served: Academic research institutions, biotechnology companies, core genomics labs.

17. SeqWell, Inc.

  • Company Name and Headquarters: SeqWell, Inc., Beverly, Massachusetts, USA

  • Product Offerings: SeqWell develops genomics tools based on its ExpressCode™ technology, which uses molecular barcoding for highly multiplexed library preparation. While they also offer bulk RNA-seq solutions, their single-cell offering is through their plexWell Single Cell solution, which enables highly multiplexed single-cell RNA-seq library preparation, allowing researchers to pool thousands of single-cell libraries for sequencing on standard NGS platforms.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): SeqWell is a smaller, emerging player in the single-cell library preparation market. Specific revenue figures are not publicly available.

  • Recent Developments, Partnerships, or Innovations:

    • Continued development and refinement of the plexWell Single Cell platform.

    • Focus on improving multiplexing capabilities and cost-efficiency for single-cell RNA-seq.

  • Competitive Positioning and Strategic Focus: SeqWell positions itself as a solution for high-throughput, cost-effective single-cell library preparation, especially beneficial for labs performing large-scale studies. Their strategic focus is on simplifying and scaling genomics workflows.

  • Key Customers or Industries Served: Academic research institutions, core genomics labs, biotechnology companies.

18. Parse Biosciences

  • Company Name and Headquarters: Parse Biosciences, Seattle, Washington, USA

  • Product Offerings: Parse Biosciences is a rapidly growing company focused on innovative single-cell sequencing solutions. Their Evercode™ technology allows for massively parallel single-cell and single-nuclei sequencing using combinatorial barcoding directly in the sample tubes, eliminating the need for complex microfluidics or specialized instruments for cell isolation. They offer Evercode WT (whole transcriptome) and Evercode TCR (T-cell receptor) for single-cell RNA sequencing.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Parse Biosciences is a significant emerging player, particularly for high-throughput and accessible single-cell RNA-seq. They have gained considerable traction due to the simplicity and scalability of their workflow. Revenue figures are not publicly disclosed, but they are recognized as a strong competitor to 10x Genomics in certain segments.

  • Recent Developments, Partnerships, or Innovations:

    • Expansion of their Evercode product line (e.g., for different sample types, expanded cell numbers).

    • Development of applications for single-nuclei RNA-seq from frozen tissues.

    • Partnerships to integrate their technology into broader research initiatives.

  • Competitive Positioning and Strategic Focus: Parse Biosciences is positioned as a highly scalable, flexible, and accessible single-cell RNA-seq solution that bypasses the need for specialized equipment, making single-cell genomics more widespread. Their strategic focus is on democratizing single-cell sequencing and expanding its applications in large-scale studies and difficult sample types.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, large-scale consortia.

19. Novogene Corporation

  • Company Name and Headquarters: Novogene Corporation, Beijing, China (with global operations including US, UK, Singapore)

  • Product Offerings: Novogene is a leading global genomics service provider. While they don’t produce their own single-cell workflow instruments, they offer comprehensive single-cell sequencing services using platforms like 10x Genomics Chromium, as well as bulk RNA-seq and DNA sequencing. They leverage Illumina and BGI sequencing platforms and provide end-to-end solutions from sample to bioinformatics analysis.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Novogene is one of the largest genomics service providers globally. Their single-cell genomics market share is within the service sector, providing access to these technologies for researchers without in-house capabilities. Their overall revenue is not publicly disclosed but is substantial.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous expansion of their service portfolio to include the latest single-cell and spatial genomics technologies.

    • Investment in bioinformatics expertise for single-cell data analysis.

    • Establishment of global service labs to better serve international clients.

  • Competitive Positioning and Strategic Focus: Novogene is positioned as a high-quality, high-throughput, and cost-effective genomics service provider. Their strategic focus is on enabling research and discovery by making advanced genomic technologies accessible to a broad customer base.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, government research labs.

20. Singleron Biotechnologies

  • Company Name and Headquarters: Singleron Biotechnologies, Nanjing, China (with operations in Germany and US)

  • Product Offerings: Singleron is a rapidly emerging player from China, focusing on developing proprietary solutions for single-cell sequencing. Their GEXSCOPE® technology offers comprehensive single-cell analysis solutions, including instruments, reagents, and bioinformatics for single-cell RNA-seq, T-cell receptor (TCR) sequencing, and multi-omics. They use a unique microfluidics-based droplet system.

  • Market Share and Estimated Revenue (Single-Cell Genomics Segment): Singleron is gaining significant traction, particularly in Asia, and expanding globally. They represent a strong challenger to established players. Revenue figures are not publicly disclosed.

  • Recent Developments, Partnerships, or Innovations:

    • Launch of new GEXSCOPE instruments and expanded reagent kits.

    • Development of spatial genomics solutions.

    • Focus on clinical applications of single-cell genomics.

    • Partnerships with leading research institutions in China and globally.

  • Competitive Positioning and Strategic Focus: Singleron positions itself as an innovative and comprehensive single-cell solution provider, offering competitive performance and increasingly diverse applications. Their strategic focus is on expanding their global market presence and driving the adoption of single-cell technologies in both research and clinical settings.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, hospitals and clinical research centers.

Contact Us

Related Posts

Scroll to Top